Search

Objective: Nonprescribed use of drugs is a clinical and public health challenge fueled by diversion of controlled opioids like buprenorphine. In this study, we report the nonprescription use of buprenorphine and buprenorphine-naloxone for the first time in India., Design: A cross-sectional observational study utilizing semistructured interviews., Setting: A tertiary care addictive disorder treatment center in India, which provides inpatient and outpatient medically oriented care that includes agonist treatment (buprenorphine) or detoxification and antagonist treatment (naltrexone)., Participants: Patients aged 18-65 years, registered at the center, and who had a history of current (within the past 6 months) nonprescription use of buprenorphine tablets were recruited., Main Outcome Measures: Participants were questioned about demographic and clinical factors and details of nonprescription use of buprenorphine and buprenorphine-naloxone using a structured questionnaire. Since both buprenorphine with naloxone and buprenorphine without naloxone are available and transacted on the street "loose" out of the blister packs, we were unable to differentiate the use of plain buprenorphine and a combination of buprenorphine- naloxone., Results: A majority of the participants used nonprescribed tablets buprenorphine and buprenorphine-naloxone with an intent to control the withdrawal symptoms, and the reason for this use was that other patients shared their prescriptions of these medications. About half of the participants injected the tablets, and liquid pheniramine was most commonly used as the solvent for dissolving the tablets. A "high" was perceived by around half of those who injected. Participants reported knowing, on an average, around 13 peers who injected the tablet buprenorphine or -buprenorphine-naloxone., Conclusion: Nonprescription use of tablets buprenorphine and -buprenorphine-naloxone is a clinical concern and also an important public health issue. Geographical and systemic expansions of the availability of buprenorphine may reduce the "demand" for nonprescribed buprenorphine, while the opportunities for diversion from treatment centers can be minimized through more careful clinical prescriptions and monitoring practices.

Aim: Use of various substances, including opioid use is often associated with coming in contact with the law- enforcement agencies. Data are scarce on the unique socio-demographic and clinical correlates from the Indian population. The current study aims to explore the clinical and socio-demographic correlations of law enforcement involvement among treatment-seeking adult males with opioid use disorder., Method: We screened adult males presenting for the treatment of opioid use disorder at the outpatient department of a tertiary care hospital in North India. We measured law enforcement involvement by asking if the patient was ever apprehended by police, had any pending legal case against them, had any history of drug trafficking, or had any history of incarceration. We divided the entire study population based on law enforcement involvement versus no involvement. We compared both the groups in terms of socio-demographic and other clinical parameters. Binary logistic regression analysis was carried out to find the independent predictors of law enforcement involvement in this population., Results: Out of a total of 204 patients with opioid use disorder, sixty-two participants (30.4%) had a history of law enforcement involvement, with all 62 of them being apprehended by the police at least once, 27 (13.2%) had a history of incarceration, 13 (6.4%) had a criminal case pending and 3 (1.5%) had a history of peddling drugs. We found out that high-risk sexual behavior, injecting drug use, and urban residence were associated with involvement with law enforcement., Conclusion: Getting involved with the law- enforcement agencies among patients with opioid use disorders may be associated with high-risk behaviors. Legal involvement among opioid-dependent individuals may also be an impediment to the treatment processes, especially when such patients are incarcerated., (Copyright © 2020 Elsevier Ltd. All rights reserved.)

Opioid use disorder is a major public health problem, and opioid replacement therapy with buprenorphine (BPN) is a clinically effective and evidence-based treatment for it. To deter misuse of the tablet through the injecting route, BPN coformulated with naloxone (BNX) in 4:1 ratio is available in many countries. Despite this, significant diversion and injecting use of the BNX combination has been reported from across the world. In this article, the pharmacological properties of BPN and BNX and the evidence for their diversion are reviewed. Also, a critical examination is made of the evidence supporting the role of naloxone in reducing the agonist effects of BPN when used through the injecting route. Based on this evidence, a hypothesis explaining the continued diversion of BNX has been proposed.

Drug use, including opioid use disorder, is one of the rapidly rising and serious problems affecting populations globally. There is a treatment gap and delay in presentation of drug users to treatment centers. The present study aimed at assessing the pathways to care among opioid-dependent individuals seeking treatment from a community-based treatment center in India. In a cross-sectional observational study conducted at a community clinic of the National Drug Dependence Treatment Centre (NDDTC), New Delhi, India, a total of 100 treatment-seeking drug users (age 18-60 years) fulfilling DSM IV TR criteria for opioid dependence were recruited. The data were collected using a semistructured pro forma based on patient self-report and the encounter form used in the World Health Organization (WHO) Pathway Study. All participants were male, were mostly married, were employed, and belonged to nuclear families. Ninety-eight percent of participants has ever used heroin in a dependent fashion and 20% were using it currently. Mean age of the participants was 40.83 years (SD 12.7). Median age of onset of heroin use was 22 years (IQR 12). Median duration of heroin use was 138 months (IQR 132). Only 21% of participants visited the community deaddiction clinic at the first contact with care. The median time for first treatment-seeking attempt was 9.5 years (IQR 7). The study findings suggest significant delay between onset of drug-related problems and first treatment contact. There is a need to increase the availability and accessibility of treatment services to reduce the delay in treatment seeking.

Internalized stigma among individuals with substance use disorders is a major barrier for accessing mental health services. This study aimed to assess internalized stigma among individuals with substance use disorders and to assess the relationship of internalized stigma with the quality of life. This cross-sectional study recruited 201 patients with a clinical diagnosis of at least opioid or alcohol use disorder according to Diagnostic and Statistical Manual 5 at a public-funded tertiary care center in India. The study participants were interviewed using a sociodemographic questionnaire, the Internalized Stigma of Mental Illness Scale (ISMIS), and the World Health Organization's Quality of Life (WHOQOL-Bref) questionnaire. Seven participants (3.5% of the sample) had mild stigma according to ISMI scores, 62 (30.8%) had moderate stigma, and 132 (65.7%) had severe stigma. The various quality-of-life domains generally had a negative correlation with the internalized stigma scores. Participants using opioids as the primary substance of use were more likely to have severe internalized stigma. The experience of internalized stigma and dissatisfaction with quality of life is quite high among people suffering with substance use disorders in India. These results emphasize the need for interventions to reduce internal perception of stigma and improve the quality of life of individuals with substance use disorders.

Background and Aims: Perceived stigma is related to the beliefs that members of stigmatized group have about the stigmatizing attitudes present in society. We present the data on perceived stigma in alcohol and opioid users seeking treatment., Methods: This study was conducted at a tertiary care de-addiction facility with recruitment of patients with substance use disorders (alcohol and opioid use). Perceived stigma was assessed using Perceived Stigma of Substance Abuse Scale (PSAS)., Results: The study included 201 participants, majority of whom were males (99.5%), educated up to 10 th std. (65.7%), with mean duration of substance use of 11.4 years. Opiates were the primary substance of abuse in the majority (83.6%) with ever-injecting drug use present in a considerable proportion (29.4%). The mean perceived stigma scale score was 21.23 ± 3.03. The perceived stigma was higher in patients from rural background, but was not associated with age, educational status, current living situation, duration of substance use and injecting drug use., Conclusion: Stigma remains an important issue among patients with alcohol and opioid use disorders. Perceived stigma could affect participation in society and health seeking behavior in substance using population, thus needs further exploration., (Copyright © 2018 Elsevier B.V. All rights reserved.)

Introduction: Emerging adulthood (between the ages 18-25years) has been conceptualized as a specific developmental stage based on unique psychosocial characteristics. Opioids are commonly used drugs in this population. Few studies have reported predictors of retention in buprenorphine maintenance treatment among opioid-dependent emerging adults, particularly from India. Moreover, no study has examined outcomes with opioid maintenance treatment among emerging adults in non-clinical trial, naturalistic settings. The current study aimed to assess retention in buprenorphine maintenance treatment among emerging adults in a naturalistic setting. Also, it aimed to assess the factors associated with retention in treatment among these individuals., Methods: The current study was a retrospective cohort study conducted at a substance use disorder treatment centre in northern part of India. The patients who received buprenorphine maintenance treatment between 1st January 2012 and 31st December 2014 were eligible for inclusion in the current study. The follow-up data of these subjects were assessed up to and including 31st March 2015. Information was retrieved on socio-demographic variables. The information related to substance use included type of substance, duration of use, age of onset, motive of use, route of administration and source of procurement. Additionally, details of buprenorphine dose, dispensing pattern, induction settings were recorded. Cox regression analysis was carried out to assess the predictors of retention in buprenorphine maintenance treatment., Results: Of 68 emerging adults, 33.8% were retained in treatment at 90days, 19.1% at 6months and 11.7% at one year. After controlling for various covariates in adjusted Cox regression analysis, substance use in first degree relatives (AHR: 2.40, 95% CI 1.33-4.31), lower daily buprenorphine dose (AHR: 0.86, 95% CI 0.78-0.94) and past month injection drug use (AHR: 0.30, 95% CI 0.14-0.66) were found to be the significant predictors of treatment dropout., Conclusions: The findings of the current study help understand the predictors of retention in buprenorphine maintenance treatment among emerging adults in a real-world situation. These findings will help guide formulation of responsive and relevant buprenorphine maintenance treatment program for the emerging adults., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Background and Aims: Tramadol is an opioid agonist which can be potentially used for maintenance treatment of patients with opioid use disorders. This chart review presents the characteristics of individuals with an ICD 10 diagnosis of opioid dependence who were maintained on tramadol for a period of at least 6 months., Methods: Records of patients seeking treatment for opioid dependence from the outpatient clinic of the National Drug Dependence Treatment Centre, Ghaziabad, India were screened. One hundred consecutive patients who received tramadol for more than 6 months were included., Results: The sample comprised exclusively of males and had a mean age of 40.9 years. The median dose of tramadol at initiation and continuation was 300 mg/day. Sixty-two patients achieved complete abstinence during the course of treatment. Greater age, longer duration of opioid use, and better follow-up adherence were associated with abstinent status. The rates of abstinence were higher among those presenting with natural opioid use as compared to others (prescription opioid use or heroin use)., Conclusion: Tramadol can be an alternative medication for harm reduction in select group of patients with opioid dependence. Further research is required to strengthen the evidence base of rational use of tramadol for maintenance treatment of patients with opioid dependence.